Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 6;22(1):590.
doi: 10.1186/s13063-021-05544-7.

The effectiveness of early colchicine administration in patients over 60 years old with high risk of developing severe pulmonary complications associated with coronavirus pneumonia SARS-CoV-2 (COVID-19): study protocol for an investigator-driven randomized controlled clinical trial in primary health care-COLCHICOVID study

Elena Bustamante Estebanez  1 , Lucía Lavín Alconero  2   3 , Beatriz Josa Fernández  1 , Monica Gozalo Marguello  4   5 , Juan Carlos López Caro  1 , Jonathan Diez Vallejo  1 , Marta Fernandez Sampedro  4   6 , Pedro Muñoz Cacho  4   7 , Carlos Richard Espiga  4   8 , María Mar García Saiz  4   9   10
Affiliations

The effectiveness of early colchicine administration in patients over 60 years old with high risk of developing severe pulmonary complications associated with coronavirus pneumonia SARS-CoV-2 (COVID-19): study protocol for an investigator-driven randomized controlled clinical trial in primary health care-COLCHICOVID study

Elena Bustamante Estebanez et al. Trials. .

Abstract

Background: There is no strong evidence that any drug is beneficial either for the treatment of SARS-CoV-2 disease or for post-exposure prophylaxis. Therefore, clinical research is crucial to generate results and evaluate strategies against COVID-19. Primary care (PC) centers, the first level of care in the health system, are in a favorable position to carry out clinical trials (CD), as they work with a large volume of patients with varied profiles (from acute to chronic pathologies). During the COVID-19 pandemic, the need for hospital admission and mortality is higher in people > 60 years. Therefore, this is a target population to try to reduce the serious complications and lethality of COVID pneumonia and to avoid overloading the hospital system. Given the pharmacological properties of colchicine (anti-inflammatory and anti-fibrotic, possible inhibition of viral replication, and inhibitory effect on coagulation activation), early treatment with colchicine may reduce the rate of death and serious pulmonary complications from COVID-19 in vulnerable patients.

Methods: The COLCHICOVID study is a randomized, multicenter, controlled, open-label parallel group (2:1 ratio), phase III clinical trial to investigate the efficacy of early administration of colchicine in reducing the development of severe pulmonary complications associated with COVID-19 infection in patients over 60 years of age with at-risk comorbidities.

Discussion: This is a pragmatic clinical trial, adapted to usual clinical practice. The demonstration that early administration of colchicine has clinical effectiveness in reducing the complications of SARS-CoV-2 infection in a population highly susceptible may mitigate the health crisis and prevent the collapse of the health system in the successive waves of the coronavirus pandemic. In addition, colchicine is a well-known medicine, simple to use in the primary care setting and with a low cost for the health system.

Trial registration: ClinicalTrials.gov NCT04416334 . Registered on 4 June 2020. Protocol version: v 3.0, dated 22 September 2020.

Keywords: Colchicine; Coronavirus; Early treatment; No hospitalized; Primary health care.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. World Health Organization. Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at.... (Accessed on 12 Feb 2020).
    1. Centers for Disease Control and Prevention. Interim clinical guidance for management of patients with confirmed 2019 novel coronavirus (2019-nCoV) infection, updated February 12, 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-manageme.... (Accessed on 14 Feb 2020).
    1. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020. 10.1001/jama.2020.4683. - PubMed
    1. Karamanou M, Tsoucalas G, Pantos K, Androutsos G. Isolating colchicine in 19th century: an old drug revisited. Curr Pharm Des. 2018;24(6):654–658. doi: 10.2174/1381612824666180115105850. - DOI - PubMed
    1. Alkadi H, Khubeiz MJ, Jbeily R. Colchicine: a review on chemical structure and clinical usage. Infect Disord Drug Targets. 2018;18(2):105–121. doi: 10.2174/1871526517666171017114901. - DOI - PubMed

Publication types

Associated data